Study
| Open-label, single-arm, phase 2, basket trial |
| BRAFV600E mutation-positive high- low-grade glioma |
| Prior radiotherapy and chemotherapy or chemoradiotherapy for high grade glioma |
| Dabrafenib 150 mg twice daily plus trametinib 2 mg once daily |
Efficacy
| High grade glioma; OR: 15/45 patients, CR:3 PR:12 |
| Low-grade glioma; OR:9/13 patients, CR:1, PR:6, minor response:2 |
Safety
| Grade >=3 AEs: 53% |
| Fatigue: 9%, headache: 5%, neutropenia: 5%, |
Lancet Oncol. 2022; 23(1):53-64.
http://doi.org/10.1016/S1470-2045(21)00578-7
Reviewed by Hasan Cagri Yildirim, MD on Mar 16, 2022
